Arvind Rao, PhD
Manage Your Profile
Center Memberships
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Global Health Equity
-
Center Membere-Health and Artificial Intelligence Initiative
-
Center MemberInstitute for Healthcare Policy and Innovation
Research Overview
Research theme: my group’s research has developed methodologies for the analysis and integrative interpretation of spatially-based, multi-modal, omics datasets (e.g: imaging, genomics, spatial profiling) for improved disease understanding and clinical decision making. Our work spans machine learning and statistical modeling for radiomics, digital pathology, predictive modeling, genomic data integration, and most recently spatial immunoprofiling and spatial transcriptomics.
Research:
a. Biomedical Image Informatics & Spatial Biology: In order to quantify the phenotypic aspects of disease, their relationships with outcome, and their genetic context, we have developed methods for the analysis of histopathology and radiology images, focusing on tumor heterogeneity. One direction of my group is to develop image analysis tools to delineate tumor image features from radiology data and, along with underlying genomic measurements, to develop AI-based predictive models to relate them to outcomes in low grade gliomas. Further, we have also investigated methodologies to link tumor imaging, genetics, and immune status in disease. Along these lines, we have embarked on measuring immune contexture in the tumor microenvironment, developing methods for the inference of the spatial architecture and patterns of infiltration of immune cells, based on multiplex-IHC and spatial transcriptomics technologies. Further, we have also developed methods for the analysis of multiparametric magnetic resonance imaging (MR) datasets in radiation oncology
b. Artificial Intelligence (AI) methods for Medicine: Our expertise is evidenced by two streams of work: (1) Developing statistical and machine learning (ML) methods to analyze and interpret multi-modal image/genomic data; (2) application of AI/ML formalisms for predictive models based on genomics, radiology and pathology imaging. These are used to assess disease stage, suitability for specific drug targets, molecular therapies & immunotherapies. More recently, we have been working on problems of bias, uncertainty quantification as well as auditing of AI solutions (in radiology and pathology image informatics) in healthcare.
Recent Publications
-
Kulkarni R, Maddox A, Bailey S, Rao A. Npj Artificial Intelligence, 2026 Dec 1; 2 (1):Journal ArticleA multimodal framework to identify molecular mechanisms driving patient group-associated morphology through the integration of spatial transcriptomics and whole slide imaging
DOI:10.1038/s44387-025-00050-6 -
Tsang AP, Krishnan SN, Kulkarni R, Bhadury S, di Magliano MP, Frankel TL, Rao A. Npj Artificial Intelligence, 2026 Dec 1; 2 (1):Journal ArticleEncoding functional edges in graphs to model spatially varying relationships in the tumor microenvironment
DOI:10.1038/s44387-026-00075-5 -
Bhadury S, Peruzzi M, Acharyya S, Eliason J, Di Magliano MP, Frankel TL, Ravikumar V, Krishnan S, Rao A. Scientific Reports, 2026 Dec 1; 16 (1):Journal ArticleInformed spatially aware patterns for multiplexed immunofluorescence data
DOI:10.1038/s41598-026-35341-8 PMID: 41521220 -
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. Clin Cancer Res, 2026 Oct 15; 32 (20): 4563 - 4570.Journal ArticleA Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.
DOI:10.1158/1078-0432.CCR-25-1114 PMID: PMC13669724 -
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. 2026 Oct 15;Additional ScholarshipClinical Trial Protocol1 from A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02
DOI:10.1158/1078-0432.34519891 -
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. 2026 Oct 15;Additional ScholarshipData from A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02
DOI:10.1158/1078-0432.c.8775241 -
Mohan A, Griffith KA, Goff LW, Crysler O, Enzler T, Cardin DB, Gunchick V, Tsang AP, Dippman D, Young AS, Olivei AC, Mannan R, Rao A, Frankel TL, Kumar-Sinha C, Zalupski MM, Sahai V. 2026 Oct 15;Additional ScholarshipSupplementary Figures and Table1 from A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02
DOI:10.1158/1078-0432.34519885 -
Elhossiny AM, Kadiyala P, Okoye JO, Hiraki HL, Procario MC, Giridharan T, Watkoske HR, Tannus Ruckert M, Wang J, Griffith BD, Bray AW, Mills JN, Espinoza CE, Zeller J, Peterson N, Bednar F, Zhang Y, Rao A, Lyssiotis CA, Szczepanski JM, Shi J, Deshpande A, Maitra A, Fertig EJ, Carpenter ES, Frankel TL, Pasca di Magliano M. Cancer Discovery, 2026 Oct 1; 16 (10): 2060 - 2084.Journal ArticleAsynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer
DOI:10.1158/2159-8290.CD-25-2001 PMID: 42165710
Featured News & Stories
Joel Eliason, Ph.D., and the power of Bayesian statistics
Arvind Rao, PhD, receives a University of Michigan Global REACH Partnership Grant